1. Modeling the Cost Savings of Continuous Pulse Oximetry and Capnography Monitoring of United States General Care Floor Patients Receiving Opioids Based on the PRODIGY Trial
- Author
-
Carla R. Jungquist, Wolfgang Buhre, Ashish Khanna, Roy Soto, Leif Saager, Fabio Di Piazza, MUMC+: Centrum voor Acute en Kritieke Zorg (3), Anesthesiologie, MUMC+: MA Anesthesiologie (9), and RS: MHeNs - R3 - Neuroscience
- Subjects
medicine.medical_specialty ,IMPACT ,Healthcare economics ,Cost savings ,Continuous monitoring ,Break-even analysis ,Continuous pulse oximetry ,Capnography ,Humans ,Medicine ,Economic model ,Pharmacology (medical) ,Oximetry ,health care economics and organizations ,Depression (differential diagnoses) ,General care floor ,Monitoring, Physiologic ,Original Research ,INDUCED RESPIRATORY DEPRESSION ,OUTCOMES ,medicine.diagnostic_test ,business.industry ,General Medicine ,RESCUE ,United States ,Pulse oximetry ,Respiratory compromise ,Respiratory depression ,Analgesics, Opioid ,Capnography monitoring ,Emergency medicine ,Cohort ,ADVERSE EVENTS ,business - Abstract
Introduction Despite the high incidence of respiratory depression on the general care floor and evidence that continuous monitoring improves patient outcomes, the cost–benefit of continuous pulse oximetry and capnography monitoring of general care floor patients remains unknown. This study modeled the cost and length of stay savings, investment break-even point, and likelihood of cost savings for continuous pulse oximetry and capnography monitoring of general care floor patients at risk for respiratory depression. Methods A decision tree model was created to compare intermittent pulse oximetry versus continuous pulse oximetry and capnography monitoring. The model utilized costs and outcomes from the PRediction of Opioid-induced respiratory Depression In patients monitored by capnoGraphY (PRODIGY) trial, and was applied to a modeled cohort of 2447 patients receiving opioids per median-sized United States general care floor annually. Results Continuous pulse oximetry and capnography monitoring of high-risk patients is projected to reduce annual hospital cost by $535,531 and cumulative patient length of stay by 103 days. A 1.5% reduction in respiratory depression would achieve a break-even investment point and justify the investment cost. The probability of cost saving is ≥ 80% if respiratory depression is decreased by ≥ 17%. Expansion of continuous monitoring to high- and intermediate-risk patients, or to all patients, is projected to reach a break-even point when respiratory depression is reduced by 2.5% and 3.5%, respectively, with a ≥ 80% probability of cost savings when respiratory depression decreases by ≥ 27% and ≥ 31%, respectively. Conclusion Compared to intermittent pulse oximetry, continuous pulse oximetry and capnography monitoring of general care floor patients receiving opioids has a high chance of being cost-effective. Trial Registration www.clinicaltrials.gov, Registration ID: NCT02811302. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-021-01779-7.
- Published
- 2021